Disease | pleural effusion disorder |
Phenotype | C0023418|leukemia |
Sentences | 10 |
PubMedID- 22587385 | The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. |
PubMedID- 20463821 | The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: a literature-based economic analysis. |
PubMedID- 22812422 | pleural effusions in patients with acute leukemia and myelodysplastic syndrome. |
PubMedID- 22550016 | Acute myeloid leukemia with leukemic pleural effusion. |
PubMedID- 24584911 | Tumor lysis syndrome in a chronic lymphocytic leukemia patient with pleural effusion after oral fludarabine and cyclophosphamide therapy. |
PubMedID- 20191333 | Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase. |
PubMedID- 22787303 | pleural effusion in patients with chronic myeloid leukemia (cml) is a rare occurrence and poorly understood. |
PubMedID- 24811835 | Recent findings: pleural effusions in patients with leukemia are most often due to infection and to a lesser extent leukemic infiltration of the pleura. |
PubMedID- 22687849 | Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites: a case report and a review of the literature. |
PubMedID- 19924787 | Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. |
Page: 1